02126.HK
JW (Cayman) Therapeutics Co. Ltd
HKSE · Healthcare · Biotechnology · CN
HKD 1.94
−3.72%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 463.6M | 276.3M | 158.2M | 173.9M | 145.7M |
| Cost of Revenue | 251.1M | 157.4M | 80.9M | 85.6M | 86.9M |
| Gross Profit | 212.5M | 118.9M | 77.3M | 88.2M | 58.8M |
| Operating Expenses | |||||
| R&D Expense | 368.6M | 141.6M | 283.0M | 413.6M | 407.8M |
| SG&A Expense | 456.5M | 219.0M | 145.2M | 117.8M | 370.6M |
| General & Admin Expense | 93.0M | — | 44.5M | 64.5M | 179.8M |
| Selling & Marketing Expense | 122.7M | — | 100.6M | 53.3M | 190.9M |
| Other Expenses | (471.0M) | — | 108.4M | 346.5M | 136.2M |
| Total Operating Expenses | 354.2M | 360.6M | 536.6M | 877.8M | 914.6M |
| Cost and Expenses | 605.3M | 518.0M | 617.5M | 963.5M | 1.0B |
| Operating Income (EBIT) | (141.7M) | (241.7M) | (459.3M) | (789.6M) | (855.9M) |
| Non-Operating | |||||
| Interest Income | 27.5M | 20.4M | 28.4M | 34.0M | 16.5M |
| Interest Expense | 8.8M | 11.1M | 12.2M | 12.4M | 6.8M |
| Net Interest Income | 18.7M | 9.3M | 16.2M | 21.6M | 9.7M |
| Other Non-Op Income/Expense | (806.6M) | (296.2M) | (131.3M) | 21.6M | 9.7M |
| Non-Operating Income (excl Interest) | 462.5M | — | (249.0K) | (34.0M) | (158.7M) |
| EBT (Pre-Tax Income) | (948.3M) | (537.9M) | (590.6M) | (768.0M) | (846.1M) |
| Income Tax Expense | 3.0M | 3.0M | — | — | — |
| Bottom Line | |||||
| Net Income | (951.3M) | (540.9M) | (590.6M) | (768.0M) | (846.1M) |
| Earnings from Cont. Ops | (951.3M) | (540.9M) | (590.6M) | (768.0M) | (846.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (951.3M) | (540.9M) | (590.6M) | (768.0M) | (846.1M) |
| Per Share | |||||
| Basic EPS | (HK$2.29) | (HK$1.30) | (HK$1.43) | (HK$1.87) | (HK$2.06) |
| Diluted EPS | (HK$2.29) | (HK$1.30) | (HK$1.43) | (HK$1.87) | (HK$2.06) |
| Revenue Per Share | HK$1.11 | HK$0.66 | HK$0.38 | HK$0.42 | HK$0.36 |
| Shares | |||||
| Basic Shares Outstanding | 416.6M | 415.8M | 413.6M | 411.5M | 410.1M |
| Diluted Shares Outstanding | 416.6M | 415.8M | 413.6M | 411.5M | 410.1M |
| Profitability Metrics | |||||
| EBITDA | (448.7M) | (162.0M) | (381.6M) | (655.7M) | (752.3M) |
| D&A | 155.5M | 79.8M | 77.5M | 99.8M | 87.1M |
| EBIT | (604.2M) | (241.7M) | (459.0M) | (755.6M) | (839.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026